Importantly, reduced levels of IFN-γ have been reported to be problematic for HCC patients, as this phenotype would be associated with a higher risk of tumor recurrence following treatment; hence, IFN-γ has been proposed as a relevant biomarker for a patient’s anti-tumor immunity [188]. Here, IFNG is linked to neoplasm.